Ajay Dhakal
Hematology · Rochester, NYNPI 1235493594
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,690 of the $4,804 with a category attached, or 97.6%. 6 manufacturers reported payments, led by AstraZeneca at 43.4% of the total. Reporting peaked in 2022 at $2,815 and has fallen 97.4% since, to $74 in 2024.
Across 9 payments — averaging $533.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Eli Lilly$2K
- Gilead$760
- Sumitomo Pharma America, Inc.$33
- Daiichi Sankyo Inc.$25
- Seagen Inc.$23
Across 45 payments — averaging $14,535 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$366K
- Pfizer$259K
- Astrazeneca UK Limited$27K
- Novartis$1K
- Merck$1K
What the payments were for
- Consulting fees$4,69098%
- Food & beverage$902%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $2,087 |
| Eli Lilly | 1 | $1,875 |
| Gilead | 2 | $760 |
| Sumitomo Pharma America, Inc. | 2 | $33 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Seagen Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$2,055
How this compares
$4,804 in reported general payments places this provider in the 65th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 20 | $290,991 |
| Exemestane | 26 | $1,880 |
| Anastrozole | 104 | $1,264 |
| Tamoxifen Citrate | 11 | $392 |
| Letrozole | 11 | $171 |
| Prochlorperazine Maleate | 13 | $147 |
Paid to pharmacies, not to this prescriber.
Other hematology in Rochester
- Paul BarrRochester$111K
- Jane LiesveldRochester$43K
- Carla CasuloRochester$43K
- Kah Poh LohRochester$9K
- Jonathan FriedbergRochester$6K
- Jason MendlerRochester$6K
- Andrew EvansRochester$5K
- Barry CollerNew York$7.9M
- Allyson OceanNew York$1.4M
- Ahmed SawasNew York$618K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.